Enterprise Value
126.6M
Cash
148.2M
Avg Qtr Burn
-29.21M
Short % of Float
19.87%
Insider Ownership
45.14%
Institutional Own.
18.43%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COMP360 (Psilocybin) Details Treatment Resistant Depression | Phase 3 Data readout | |
COMP360 (Psilocybin) Details Post-traumatic stress disorder | Phase 2 Data readout | |
COMP360 (Psilocybin) Details Anorexia nervosa | Phase 2 Interim update |